bit.bio

How long does it take you to generate reliable data from your human iPSC-derived cells? Traditional directed differentiation protocols can take weeks or months, often suffering from lot-to-lot variability. At #ISSCR2026 in Montreal, our team will be showing how deterministic cell programming technology, opti-ox™, overcomes these limitations. Powered by opti-ox, our human iPSC-derived ioCells are consistent, defined, functional and ready for data gathering within days. William Bernard, Gianmarco Mastrogiovanni and Dario Pacitti will be showcasing the versatility of human iPSC-derived cells powered by opti-ox across 4 different research areas. Come check out the data at our posters: 1. ADME/Tox | Demonstrating functional CYP450 enzyme activity in iPSC-derived hepatocytes for reliable, scalable DILI assays. 2. Neurodegeneration | Uncovering alternatively spliced transcripts in TDP-43 mutant ioMotor and ioGlutamatergic Neurons to unlock new insights into ALS and FTD. 3. Metabolic disease | Developing functional human iPSC-derived adipocytes exhibit a robust thermogenic response following forskolin stimulation. 4. Neuroimmunology | Modelling demyelinating disease with oligodendrocyte-like cells that show elevated MBP expression in co-culture. Drop the team a message to schedule a meet-up in Montréal, or visit the posters to chat with the team and see how ioCells can advance your research. #ISSCR2026 #iPSC #TranslationalResearch #Neuroscience #Hepatotoxicity #DrugDevelopment #optiox

"More reliable healthcare solutions begin with more reliable science." Our CEO, Emma Pepperell, PhD, recently spoke with TechRound about the shifting focus in UK HealthTech, moving from an "innovation-first" to an "evidence-first" approach. At bit․bio, we believe that dependable healthcare does not just start in the clinic. Consistency must be built into every stage of the medical process, starting right at the foundation with preclinical drug development and toxicity testing. Read Emma's full insights alongside other industry leaders here: https://hubs.ly/Q04nc_8m0 #HealthTech #DrugDiscovery #LifeSciences #optiox #ioCells #PreclinicalToxicology

Are you interested in a reliable, easy-to-use human model of neuroinflammation? Let’s connect at #FENS2026. Our team will be at booth #24, ready to share how ioCells are helping neuroscientists build human-relevant in vitro models. Make sure to attend our posters to find NEW functional data from our latest disease model, ioMicroglia P2RY12 null/null. We’ll be showcasing how the model of neuroinflammation displays a measurable phenotype with a clear chemotaxis ablation towards ATP, and demonstrating how human iPSC-derived ioMicroglia can be added straight from thaw into your organoid models. You can also visit our posters to learn more about modelling Alzheimer’s disease and ALS/FTD in vitro. What else is happening? Bricks of Biology Competition! Race the clock: Be the fastest to correctly build the brick-style neuron model. The quickest brain at the end of each day gets to keep the kit! The competition will be running all week, so drop by booth #24! Featured user posters - DissOrg: A high-throughput 2D cortical organoid-derived neuronal and glial co-culture platform that is capable of synaptic plasticity Hana Toda Sheldon, German Center for Neurodegenerative Diseases (DZNE) - A calcium imaging pipeline to detect and quantify compound-specific effects in human and mouse astrocytes Jeremy Krohn, German Center for Neurodegenerative Diseases (DZNE) - Investigating astrocyte metabolism in a mouse model of acute stress Kratika Mujmer, University of Bristol Want to talk through your research or see where ioCells could fit into your workflow? Come and talk to us at booth 24! #Neuroscience #HumanCells #CRISPR #iPSC #ioCells #optiox

What makes our newly launched human iPSC-derived ioHepatocytes unique?  Powered by opti-ox™ technology, these functional cells are built to bring much-needed consistency, scalability, and human relevance to early-stage hit-to-lead and in vitro ADME-Tox profiling. Identify toxicity risks sooner, with: - Verified human relevance: They replicate primary human hepatocyte (PHH)  morphology, binucleation, and transcriptomic signatures, giving you full confidence that your data reflects true human biology. - Extended experimental window: Need to do long-term dosing? ioHepatocytes maintain viability, albumin secretion, and CYP450 activity for >17 days in 2D culture, allowing for long-term toxicity studies earlier during hit-to-lead optimisation. - Predictive drug metabolism: Expressing Phase I, II, and III genes, ioHepatocytes successfully mirror PHH DILI responses, providing a familiar predictive model with a scalable, reproducible supply. Dive into the data: https://hubs.ly/Q04n1NCv0 #DrugDiscovery #Hepatotoxicity #ADMETox #iPSC #Biotech #InVitro #ToxicityScreening #optiox #ioCells

The drug development landscape is evolving. With the rise of New Approach Methodologies (NAMs) and the passage of FDAMA 2.0, we are seeing a vital transition toward highly predictive, human-specific preclinical research. In our latest blog, we sat down with four leading experts to explore how human iPSC-derived cells are providing a foundation for this transition. Swipe through to see their insights on the future of drug discovery, and read the full article here: https://hubs.ly/Q04mNhB30

What did the Human Cell Forum 2026 mean to those who attended? For the researchers in the room, it was an opportunity to see new science and ideas presented exactly as they are happening. It went far beyond exchanging emails or reading research papers. The event provided attendees with a vital space to bring academia and industry together. By coming together face-to-face, academic scientists, technology developers, and regulators were able to truly explore each other's experiences, discuss challenges, and even learn from past failures. Most importantly, the day was about building the trust required to forge new collaborations. It enabled the community to consider what is needed to transition to human-based science and to work toward making critical drugs more widely available at a lower cost. Watch our highlights reel below to catch the energy from the day!  #HumanCellForum #DrugDiscovery #Biotech #Collaboration #LifeSciences #ioCells #optiox

NEW ioCELLS ALERT! bit․bio unveils ioHepatocytes to transform drug safety testing by solving the challenge of human hepatocyte availability. The Early Access launch of ioHepatocytes marks a significant milestone in our mission to democratise access to consistent, defined human cells. By applying our deterministic cell programming, opti-ox™, to generate human iPSC-derived hepatocytes, we are addressing a major challenge associated with primary human material: sourcing sufficient high-quality, consistent cells. Our technology enables the generation of cells on a massive scale, with unprecedented lot-to-lot consistency.  The lot consistency combined with sustained in vitro function allows researchers to conduct longer-term toxicity studies earlier in the drug development process and generate more reproducible data without relying on expensive and technically complex models. For the first time, researchers have access to an in vitro liver model that offers the physiological relevance of primary human cells with the scalability and consistency required for modern, high-throughput workflows. By enabling an accurate representation of human biology in early stages of toxicology studies, ioHepatocytes offer a path towards enhanced clinical translation in preclinical drug development. Read the press release: https://lnkd.in/ean_friC  #DrugDiscovery #optiox #ioCells #Hepatocytes #LifeSciences #HealthTech #BiotechMilestone

"We are struggling with donor inconsistencies, availability, and a limited functional window." Most preclinical toxicologists say the same thing about primary human hepatocytes. Stalled timelines due to unpredictable donor availability and the time sink of continuous lot-to-lot validation have become the industry norm. But they shouldn't be. Today, we are proud to announce the Early Access launch of ioHepatocytes. Powered by opti-ox™, these highly consistent and functional human iPSC-derived hepatocytes provide a reliable, scalable solution for in vitro preclinical toxicity studies. For the first time, scientists will have access to the physiological relevance of primary hepatocytes with the scalability and cost-effectiveness of immortalised lines, offering unparalleled consistency for early-stage hit-to-lead and in vitro ADME-Tox profiling. By overcoming the sourcing and quality challenges of primary cells, ioHepatocytes enable reproducible, longer-term toxicity studies earlier in drug development, without the need for costly or complex alternative models. Learn more about securing early access here: https://hubs.ly/Q04lQJQr0 #ioCells #optiox #PreclinicalToxicology #ADMETox #InVitroToxicology #Hepatocytes #DILI

How does a cell decide what to become? Transcription factors hold much of the answer, but systematically mapping their influence on cell identity has been out of reach - until now. Join this webinar today with Parse Biosciences and bit․bio to discover how we are combining single-cell perturbation with opti-ox™ deterministic cell programming to create a map of cell fate. What you’ll learn: - The principles of massively parallel causal transcriptomics and how high-throughput perturbation experiments can resolve transcription factor function at single-cell resolution - Experimental design considerations for systematically mapping transcription factor inputs to cell fate outputs - How consistent, defined human cells improve interpretability and reproducibility in large-scale perturbation studies - The role of causal, perturbation-based datasets in training predictive models of cellular response - Implications for drug discovery, disease modelling, and scalable production of human iPSC-derived cells  Register here: https://hubs.ly/Q04lH1sr0 #optiox #iPSCs #DrugDiscovery